Article info

Download PDFPDF

The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation

Authors

  1. Correspondence to Janis M Taube, Department of Dermatology, Johns Hopkins School of Medicine, Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, MD, United States; jtaube1{at}jhmi.edu
View Full Text

Citation

Taube JM, Akturk G, Angelo M on behalf of the Society for Immunotherapy of Cancer (SITC) Pathology Task Force., et al
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation

Publication history

  • Accepted January 9, 2020
  • First published May 15, 2020.
Online issue publication 
May 15, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.